What We Know About Stage II and III Colon Cancer: It's Still Not Enough.

Puccini, Alberto; Berger, Martin Dave; Zhang, Wu; Lenz, Heinz-Josef (2017). What We Know About Stage II and III Colon Cancer: It's Still Not Enough. Targeted oncology, 12(3), pp. 265-275. Springer 10.1007/s11523-017-0494-5

Text Puccini2017_Article_WhatWeKnowAboutStageIIAndIIICo.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (435kB)

The introduction of oxaliplatin as adjuvant treatment for stage III colon cancer in 2004 has been the last practice changing progress in adjuvant treatment for patients with early colon cancer. Since then, many prognostic and predictive biomarkers have been studied, but only DNA mismatch repair status has been validated as having an important prognostic value. Accordingly, TNM and clinical-pathological patterns, such as pT4 lesions and lymph node sampling <12 nodes, are the main factors that guide physicians' choice regarding adjuvant treatment. More recently, many biomarkers showed promising results: POLE, ErbB2, CDX2, SMAD4, BRAF and KRAS. In addition to these, immune-contexture, molecular classification, and gene signatures could become new ways to better classify colon cancer patients with more discriminatory power than TNM. The aim of this review is to report the state-of-the-art of prognostic and predictive factors in the adjuvant setting and which of these could modify clinical practice and maybe replace TNM classification.

Interest & Impact

Downloads

161 since deposited on 12 Jul 2018
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item